SUBSCRIBE
SUBSCRIBE

Panbela Therapeutics Inc.

IN THE PRESS
Policy
Panbela Announces Issuance of New Patent in Australia Patent is for Claims of a Novel Process for the Production of SBP-101
July 17, 2023
 · 
8 min read
Drug Development
Panbela Announces Preliminary Safety Analysis for ASPIRE Trial
July 10, 2023
 · 
6 min read
Drug Development
Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis
June 28, 2023
 · 
6 min read
BioMidwest
Panbela Announces Poster Presentation at the Endocrine Society Meeting: Polyamine Inhibition and β-Cell Preservation in Recent Onset Type 1 Diabetes
June 26, 2023
 · 
8 min read
BioMidwest
Panbela Announces Closing of Approximately $8.5 Million Public Offering
June 21, 2023
 · 
5 min read
BioMidwest
Panbela Announces Pricing of Approximately $8.5 Million Public Offering
June 16, 2023
 · 
5 min read
BioMidwest
Panbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy
June 13, 2023
 · 
8 min read
BioMidwest
Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting: Evaluating the Potential of CPP-1X (Eflornithine) in Recent Onset Type 1 Diabetes
June 1, 2023
 · 
8 min read
BioMidwest
Panbela Announces 1-for-30 Reverse Stock Split Effective June 1, 2023
May 31, 2023
 · 
5 min read
Business
Panbela Announces Clinical Trial with Moffitt Cancer Center for Phase I/II Program in STK11 Mutant Non-Small Cell Lung Cancer
May 22, 2023
 · 
7 min read
Load More
JOBS